Skip to main content
Erschienen in: Digestive Diseases and Sciences 12/2015

01.12.2015 | Original Article

Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas

verfasst von: Channa R. Jayasekera, Ryan B. Perumpail, David T. Chao, Edward A. Pham, Avin Aggarwal, Robert J. Wong, Aijaz Ahmed

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite the availability of safe and effective direct-acting antiviral drugs (DAAs), the vast majority of patients with chronic hepatitis C (HCV) in the USA remain untreated, in part due to lack of access to specialist providers.

Aims

To determine the effectiveness of DAA-based treatment in medically underserved areas in California, in a healthcare model dependent on task-shifting—wherein a visiting hepatologist assesses patients for treatment eligibility, but subsequent routine follow-up evaluation of patients prescribed treatment is devolved to a part-time licensed vocational nurse under remote supervision of the hepatologist.

Methods

We retrospectively determined rates of sustained virologic response 12 weeks after treatment completion (SVR-12), adverse events, and treatment discontinuations in patients who received sofosbuvir-based DAA regimens between December 2013 and November 2014.

Results

Despite limited specialist provider involvement in medically underserved areas, all but two of 58 patients completed treatment, and 88 % of patients achieved the curative endpoint of undetectable HCV RNA 12 weeks after completing treatment (sustained virologic response, SVR-12). Almost 80 % of patients with cirrhosis and 85 % of patients with prior treatment experience achieved SVR-12.

Conclusions

Treatment effectiveness with sofosbuvir-based regimens in medically underserved areas utilizing task-shifting from a specialist to a mid-level provider is comparable to those achieved in pivotal clinical trials for these regimens, and to “real-world” experiences of tertiary care centers in the USA.
Literatur
1.
Zurück zum Zitat Hepatitis and Liver Cancer. A national strategy for prevention and control of hepatitis B and C. Washington, DC: Institute of Medicine; 2010. Hepatitis and Liver Cancer. A national strategy for prevention and control of hepatitis B and C. Washington, DC: Institute of Medicine; 2010.
2.
Zurück zum Zitat Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 2014;160:293–300.PubMedCentralCrossRefPubMed Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 2014;160:293–300.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Reau N. HCV testing and linkage to care: expanding access: HCV testing and linkage to care. Clin. Liver Dis. 2014;4:31–34.CrossRef Reau N. HCV testing and linkage to care: expanding access: HCV testing and linkage to care. Clin. Liver Dis. 2014;4:31–34.CrossRef
4.
Zurück zum Zitat Kredo T, Adeniyi FB, Bateganya M, Pienaar ED. Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapy. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester. doi:10.1002/14651858.CD007331.pub3. Accessed 12 Dec 2014. Kredo T, Adeniyi FB, Bateganya M, Pienaar ED. Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapy. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester. doi:10.​1002/​14651858.​CD007331.​pub3. Accessed 12 Dec 2014.
6.
Zurück zum Zitat Chirikov VV, Shaya FT, Howell CD. Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in Medicare patients. Hepatology. 2015;62:68–78.CrossRefPubMed Chirikov VV, Shaya FT, Howell CD. Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in Medicare patients. Hepatology. 2015;62:68–78.CrossRefPubMed
7.
Zurück zum Zitat Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb. Mortal. Wkly. Rep. 2015;64:453–458.PubMed Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb. Mortal. Wkly. Rep. 2015;64:453–458.PubMed
8.
Zurück zum Zitat Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.CrossRefPubMed Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.CrossRefPubMed
9.
Zurück zum Zitat Yehia BR, Schranz AJ, Umscheid CA, Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE. 2014;9:e101554.PubMedCentralCrossRefPubMed Yehia BR, Schranz AJ, Umscheid CA, Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE. 2014;9:e101554.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann. Intern. Med. 2015;162:397.PubMedCentralCrossRefPubMed Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann. Intern. Med. 2015;162:397.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C Virus. Ann. Intern. Med. 2015;162:407.CrossRefPubMed Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C Virus. Ann. Intern. Med. 2015;162:407.CrossRefPubMed
12.
Zurück zum Zitat Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N. Engl. J. Med. 2011;364:2199–2207.CrossRefPubMed Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N. Engl. J. Med. 2011;364:2199–2207.CrossRefPubMed
13.
Zurück zum Zitat Rongey C, Shen H, Hamilton N, Backus LI, Asch SM, Knight S. Impact of rural residence and health system structure on quality of liver care. PLoS ONE. 2013;8:e84826.PubMedCentralCrossRefPubMed Rongey C, Shen H, Hamilton N, Backus LI, Asch SM, Knight S. Impact of rural residence and health system structure on quality of liver care. PLoS ONE. 2013;8:e84826.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet. 2014;384:1756–1765.CrossRef Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet. 2014;384:1756–1765.CrossRef
15.
Zurück zum Zitat Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013;368:1878–1887.CrossRefPubMed Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013;368:1878–1887.CrossRefPubMed
16.
Zurück zum Zitat Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014;370:1993–2001.CrossRefPubMed Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014;370:1993–2001.CrossRefPubMed
17.
Zurück zum Zitat Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013;368:1867–1877.CrossRefPubMed Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013;368:1867–1877.CrossRefPubMed
18.
Zurück zum Zitat Jensen DM, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort (HCV-TARGET). The Liver Meeting: American Association for the Study of Liver Diseases, Boston, MA. Abstract 45: 2014. Jensen DM, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort (HCV-TARGET). The Liver Meeting: American Association for the Study of Liver Diseases, Boston, MA. Abstract 45: 2014.
19.
Zurück zum Zitat Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment. Pharmacol. Ther. 2015;42:559–573.CrossRefPubMed Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment. Pharmacol. Ther. 2015;42:559–573.CrossRefPubMed
Metadaten
Titel
Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas
verfasst von
Channa R. Jayasekera
Ryan B. Perumpail
David T. Chao
Edward A. Pham
Avin Aggarwal
Robert J. Wong
Aijaz Ahmed
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 12/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3911-6

Weitere Artikel der Ausgabe 12/2015

Digestive Diseases and Sciences 12/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.